These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 186438)

  • 1. Immune inhibition of virus release from herpes simplex virus-infected cells.
    Skinner GR; Mushi EZ; Whitney JE
    Intervirology; 1975-1976; 6(4-5):296-308. PubMed ID: 186438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of virus-specific antigens in extracts from herpes simplex virus-infected cells by a Cr release inhibition test.
    Kutinová L; Vonka V
    Infect Immun; 1978 Jun; 20(3):587-91. PubMed ID: 78899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of staphylococcal protein A on complement-potentiated neutralization of herpes simplex virus and immune lysis of virus-infected cells.
    Austin RM; Daniels CA
    Infect Immun; 1975 Oct; 12(4):821-7. PubMed ID: 172447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus antigens and antibodies: a survey of studies based on quantitative immunoelectrophoresis.
    Vestergaard BF
    Rev Infect Dis; 1980; 2(6):899-913. PubMed ID: 6164087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigens of herpes simplex virus of oral and genital origin.
    Wildy P
    Cancer Res; 1973 Jun; 33(6):1465-8. PubMed ID: 4124113
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the neutralization of herpes simplex virus. VI. The mode of action of complement upon antibodysensitized virus.
    Yoshino K; Kishie T
    Jpn J Microbiol; 1973 Jan; 17(1):63-70. PubMed ID: 4349352
    [No Abstract]   [Full Text] [Related]  

  • 7. The herpes simplex virus type 1 US7 gene product is a 66K glycoprotein and is a target for complement-dependent virus neutralization.
    Sullivan V; Smith GL
    J Gen Virol; 1988 Apr; 69 ( Pt 4)():859-67. PubMed ID: 2833569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreproducibility of neutralization of herpes simplex virus under conditions where antibody is not in excess.
    Shariff D; Hallworth JA; Buchan A; Skinner GR
    Intervirology; 1987; 28(2):100-4. PubMed ID: 2832344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and characterization of specific antisera to individual glycoprotein antigens comprising the major glycoprotein region of herpes simplex virus type 1.
    Eberle R; Courtney RJ
    J Virol; 1980 Sep; 35(3):902-17. PubMed ID: 6252346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type specific and type common antigens in cells infected with herpes simplex virus type 1 and on the surfaces of naked and enveloped particles of the virus.
    Honess RW; Powell KL; Robinson DJ; Sim C; Watson DH
    J Gen Virol; 1974 Feb; 22(2):159-69. PubMed ID: 4132223
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune inhibition of virus release from herpes simplex virus-infected cells by human sera.
    Shariff DM; Hallworth J; Desperbasques M; Buchan A; Skinner GR
    Intervirology; 1988; 29(3):125-32. PubMed ID: 2846463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against herpes simplex virus in a group of healthy humans without reactions to herpes simplex virus antigens in blasttransformation assays.
    Møller-Larsen A
    J Clin Lab Immunol; 1986 Jul; 20(3):121-7. PubMed ID: 3018253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway.
    Perrin LH; Joseph BS; Cooper NR; Oldstone MB
    J Exp Med; 1976 May; 143(5):1027-41. PubMed ID: 177712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoproteins with type common and type specific antigenic sites excreted from cells infected with herpes simplex virus types 1 and 2.
    Randall RE; Killington RA; Watson DH
    J Gen Virol; 1980 Jun; 48(Pt 2):297-310. PubMed ID: 6156995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Human hybridoma neutralizing antibodies to the herpes simplex virus].
    Kushch AA; Tugizov ShM; Terletskaia EN; Posevaia TA; Nikitina AA; L'vov ND; Barinskiĭ IF
    Vopr Virusol; 1992; 37(5-6):264-6. PubMed ID: 1337804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Participation of three major glycoprotein antigens of herpes simplex virus type 1 early in the infectious cycle as determined by antibody-dependent cell-mediated cytotoxicity.
    Norrild B; Shore SL; Cromeans TL; Nahmias AJ
    Infect Immun; 1980 Apr; 28(1):38-44. PubMed ID: 6247286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of immediate early, early and late antigens in herpes simplex virus type 1 infected cells.
    Beth E; Giraldo G; Bernhard M
    Biomedicine; 1976 Dec; 25(10):366-8. PubMed ID: 189852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of monoclonal antibodies against nucleocapsid proteins of herpes simplex virus types 1 and 2.
    Zweig M; Heilman CJ; Rabin H; Hopkins RF; Neubauer RH; Hampar B
    J Virol; 1979 Nov; 32(2):676-8. PubMed ID: 91687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs.
    Lebon P
    J Gen Virol; 1985 Dec; 66 ( Pt 12)():2781-6. PubMed ID: 2999320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of antibodies to Herpes simplex virus types 1 and 2 by complement-dependent antibody lysis of infected cells.
    McClung H; Seth P; Rawls WE
    Am J Epidemiol; 1976 Aug; 104(2):181-91. PubMed ID: 60057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.